SCHEMBL1590749

SCHEMBL1590749

CCOc1ncccc1C1(Cl)C(=O)Nc2ccc(Cl)cc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.41
ADAMTS5 Q9UNA0 3/20 0.40
MAOB P27338 1/20 0.40
NPC1 O15118 2/20 0.40
TSHR P16473 1/20 0.40
ADCY8 P40145 1/20 0.39
MAPK1 P28482 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PGR P06401 2/20 0.39
IP6K1 Q92551 1/20 0.38
CBX7 O95931 2/20 0.38
CDYL Q9Y232 2/20 0.38
CDYL2 Q8N8U2 1/20 0.38
CDY1; CDY1B Q9Y6F8 1/20 0.38
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
MAPT P10636 1/20 0.37
SNRNP200 O75643 1/20 0.36
MGAM O43451 1/20 0.36
HTR1A P08908 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1464983 0.88 ADAMTS5 (0.47) IDO1ADAMTS5MAOBPGRCBX7
SCHEMBL1590714 0.85 IDO1 (0.45) IDO1ADAMTS5NPC1TSHRADCY8
SCHEMBL1590596 0.85 IDO1 (0.40) IDO1ADAMTS5MAOBNPC1TSHR
SCHEMBL1479564 0.84 AVPR1B (0.39) ADAMTS5MAPK1PGRIP6K1MEN1
Pyridine SCHEMBL5695608 0.84 ADAMTS5 (0.43) IDO1ADAMTS5MAOBPGRCBX7
SCHEMBL1589139 0.83 L3MBTL1 (0.39) NPC1TSHRADCY8MAPK1L3MBTL1
SCHEMBL4590087 0.82 ADCY8 (0.43) IDO1MAOBTSHRADCY8MAPK1
SCHEMBL1590667 0.81 IDO1 (0.44) IDO1NPC1TSHRADCY8MAPK1
SCHEMBL27821573 0.80 IDO1 (0.41) IDO1ADAMTS5MAOBNPC1TSHR
SCHEMBL1590715 0.80 IDO1 (0.41) IDO1ADAMTS5MAOBNPC1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150158845-A1 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSIN-DEPENDENT DISEASES ABBVIE DEUTSCHLAND (DE) 2015-06-11 US disclosed
US-9023854-B2 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressin-dependent diseases AbbVie Deutschland GmbH & Co. KG (DE) 2015-05-05 US disclosed
EP-2231645-B1 5-Halogen-substituted oxindole derivatives and their use in the manufacture of a medicament for the treatment of vasopressin-dependent diseases ABBOTT GMBH & CO KG (DE) 2012-10-03 EP disclosed
US-20110092516-A1 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSIN-DEPENDENT DISEASES ABBOTT GMBH & CO. KG 2011-04-21 US disclosed
EP-2231645-A2 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSINE-DEPENDENT DISEASES Abbott GmbH & Co. KG (DE) 2010-09-29 EP disclosed
WO-2009071689-A2 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSINE-DEPENDENT DISEASES ABBOTT GMBH & CO. KG (DE) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092516-A1 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSIN-DEPENDENT DISEASES AVPR2, AVPR1B, AVPR1A IDO1 2206/4885ADAMTS5 127/4885MAOB 776/4885
US-20150158845-A1 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSIN-DEPENDENT DISEASES AVPR2, AVPR1B, AVPR1A IDO1 2206/4885ADAMTS5 127/4885MAOB 776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.